We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Screening for Hemoglobinopathies in Pregnant Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04029142
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : October 14, 2021
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This prospective monocentric study project is to identify hemoglobinopathies in pregnant women in order to optimize antenatal care and to investigate the prevalence of hemoglobinopathies in pregnant women in Switzerland.

Condition or disease Intervention/treatment
Hemoglobinopathies Diagnostic Test: Review of routine lab data

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Screening for Hemoglobinopathies in Pregnant Women
Actual Study Start Date : July 3, 2019
Estimated Primary Completion Date : September 2025
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Diagnostic Test: Review of routine lab data
    Review of routine lab data from pregnant women (first trimester)

Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. identification of hemoglobinopathies [ Time Frame: single time point assessment at baseline ]
    identification of hemoglobinopathies by investigating routine lab samples


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
pregnant women seen at the Frauenklinik at University Hospital Basel
Criteria

Inclusion Criteria:

  • pregnant women seen at the Frauenklinik at University Hospital Basel

Exclusion Criteria:

  • pregnant women with already known hemoglobinopathy
  • refusal of participation
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04029142


Contacts
Layout table for location contacts
Contact: Gabriela Amstad Bencaiova, Dr. med 0041 61 556 5922 gabriela.amstad@usb.ch
Contact: Irene Hoesli, Prof. Dr. 0041 61 265 9017 irene.hoesli@usb.ch

Locations
Layout table for location information
Switzerland
Frauenklinik University Hospital Basel Recruiting
Basel, Switzerland, 4031
Contact: Gabriela Amstad Bencaiova, Dr. med    +41 61 556 59 22    gabriela.amstad@usb.ch   
Sub-Investigator: Franziska Geissler, Dr.med         
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Irene Hoesli, Prof. Dr. Frauenklinik Universitätsspital Basel
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT04029142    
Other Study ID Numbers: 2019-01065; sp19Amstad
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: October 14, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Basel, Switzerland:
thalassemia
sickle cell anaemia
molecular genetic analysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinopathies
Hematologic Diseases
Genetic Diseases, Inborn